IQVIA Publications in ASCO20 Virtual Scientific Program
Scientific Poster
May 21, 2020
As the American Society of Oncology (ASCO) 2020 annual meeting moved to a virtual format, IQVIA’s oncology experts contributed to several publications across multiple topics and indications.  
Featured Abstracts
See below for more ASCO20 abstracts from IQVIA authors.  

MSI/MMR test usage and checkpoint inhibitor practices in Europe.

Abstract in ASCO20 Virtual Scientific Program: Health Services Research and Quality Improvement

AUTHORS

Bradley Smith, Jeffrey Hodge, Caroline Anger, Fil Manuguid, Kriti Jindal; IQVIA, Marblehead, MA; IQVIA, Durham, NC; IQVIA, London, United Kingdom

View Abstract


Real-world clinical and economic burden associated with hospitalization in metastatic triple-negative (ER-/PR-/HER2-) breast cancer.

Abstract in ASCO20 Virtual Scientific Program: Health Services Research and Quality Improvement

AUTHORS

Amie Tan, Xu Han, Aimee Near, Jenny Tse, Luciana Preger; Genentech, Inc., South San Francisco, CA; IQVIA, Durham, NC

VIEW ABSTRACT


Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.

Abstract in ASCO20 Virtual Scientific Program: Health Services Research and Quality Improvement

AUTHORS

Lawrence H. Kushi, Laura Lasiter, Andrew J. Belli, Marley Boyd, Suanna S. Bruinooge, Jennifer Christian, Elizabeth Garrett-Mayer, Eric Hansen, Rebecca Honnold, Ruth Pe Benito, Yanina Natanzon, Lori Sakoda, Donna R. R Rivera, Whitney Rhodes, Nicholas J. Robert, Elad Sharon, Connor Sweetnam, Joseph Wagner, Mark S. Walker, Jeff Allen; Kaiser Permanente, Oakland, CA; Friends of Cancer Research, Washington, DC; COTA, Inc., New York, NY; McKesson Life Sciences, The Woodlands, TX; American Society of Clinical Oncology, Alexandria, VA; IQVIA, Research Triangle Park, NC; Tempus Labs, Chicago; Tempus, Chicago, IL; Syapse, San Francisco, CA; Kaiser Permanente Northern California, Division of Research, Oakland, CA; National Cancer Institute, Rockville, MD; Concerto HealthAI, Memphis, TN; 10101 Woodloch Forest, The Woodlands, TX; National Cancer Institute, Bethesda, MD; Syapse Inc., San Francisco, CA; IQVIA, Plymouth Meeting, PA; ACORN Research LLC, Memphis, TN

VIEW ABSTRACT 


Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration.

Abstract in ASCO20 Virtual Scientific Program: Health Services Research and Quality Improvement

AUTHOR(S)

Donna R. R Rivera, Laura Lasiter, Jennifer Christian, Lindsey Enewold, Janet L. Espirito, Eric Hansen, Henry J. Henk, Lawrence H. Kushi, Daniel Lane, Yanina Natanzon, Ruth Pe Benito, Erik Rasmussen, Nicholas J. Robert, Mark Stewart, Connor Sweetnam, Olga Tymejczyk, Emily Valice, Joseph Wagner, Alia Zander, Jeff Allen; National Cancer Institute, Rockville, MD; Friends of Cancer Research, Washington, DC; IQVIA, Research Triangle Park, NC; National Cancer Institute, Bethesda, MD; McKesson Life Sciences, The Woodlands, TX; COTA, Inc., New York, NY; OptumLabs, Shakopee, MN; Kaiser Permanente, Oakland, CA; COTA Healthcare, Boston, MA; Syapse, San Francisco, CA; Tempus, Chicago, IL; Flatiron Health, New York, NY; 10101 Woodloch Forest, The Woodlands, TX; Syapse Inc., San Francisco, CA; Kaiser Permanente Division of Research, Oakland, CA; IQVIA, Plymouth Meeting, PA

VIEW ABSTRACT 


Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.

Abstract in ASCO20 Virtual Scientific Program: Hematologic Malignancies—Plasma Cell Dyscrasia

AUTHORS

Joshua Ryan Richter, Jason Yeaw, Drishti Shah, Ruthwik Anupindi, Suneel Kudaravalli, Stojan Zavisic; The Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai, New York, NY; IQVIA, San Francisco; IQVIA, Falls Church, VA; Oncopeptides, Mountain View, CA; Oncopeptides AB, Stockholm, Sweden

VIEW ABSTRACT


Burden of relapsed/refractory (RR) acute myeloid leukemia.

Abstract in ASCO20 Virtual Scientific Program: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

AUTHORS

Sumeet Panjabi, Dionne M. Hines, Catherine Balderston McGuiness, Emre Yucel, Steven Yea, Zachariah McIver, Rolin L Wade; Amgen, Inc., South San Francisco, CA; IQVIA, Plymouth Meeting, PA; Amgen, Inc, Thousand Oaks, CA

VIEW ABSTRACT


A retrospective analysis of CDK4/6 inhibitors among adult female patients with metastatic breast cancer.

Abstract in ASCO20 Virtual Scientific Program: Breast Cancer—Metastatic

AUTHORS

Silvia Comis, Thenmozhi Kandasamy, Alysa J Perrin, Kelley Kent, Mahendra Dulawat, Arun Chhikara, Nitish Ranjan; IQVIA, Milan, Italy; IQVIA, Inc., Durham, NC

VIEW ABSTRACT


Prognostic factors impacting survival in early HER2-positive breast cancer (BC): Results from a 1,142 patients database study.

Abstract in ASCO20 Virtual Scientific Program: Breast Cancer - Local/Regional/Adjuvant

AUTHORS

Roberto Hegg, Andre Mattar, Maurício Rocha, Renato Watanabe Oliveira, Guilherme Silva Julian, Luiz Henrique Gebrim; Hospital Pérola Byington, São Paulo, Brazil; Roche Brazil, São Paulo, Brazil; IQVIA, São Paulo, Brazil

VIEW ABSTRACT


Comparative effectiveness of immune-checkpoint inhibitors as first-line treatment for advanced nonsquamous non-small cell lung cancer patients: A network meta-analysis and a systematic review.

Abstract in ASCO20 Virtual Scientific Program: Lung Cancer—Non-Small Cell Metastatic

AUTHORS

Roberto Jorge Bitton, Natalia Jacob, Juan Manuel Carrera, Ezequiel Cayetano Perez; IQVIA, Buenos Aires, Argentina; Quintiles, Buenos Aires, Argentina

VIEW ABSTRACT
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.